Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systemic review

JAMA

Volumn 279, Issue 23, 1998, Pages 1903-1907

  Messerli, Franz H ^a,c   Grossman, Ehud ^b   Goldbourt, Uri ^b  

^a OCHSNER MEDICAL CENTER   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROCHLOROTHIAZIDE; METOPROLOL; PINDOLOL; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; DIURESIS; ELDERLY CARE; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; STROKE;

EID: 0032540714     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.23.1903     Document Type: Article

References (63)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153: 154-183.
3. Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984;310:830-837.
4. Veterans Administrative Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Circulation. 1972;45:991-1004.
5. Kuramoto K, Matsushita S, Kuwajima I, Murakami M. Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J. 1981; 22:75-85.
6. Treatment of mild hypertension in the elderly: a study initiated and administered by the National Heart Foundation of Australia. Med J Aust. 1981; 2:398-402.
7. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.
8. Maxwell MH, Ford CE. Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry. J Cardiovasc Pharmacol. 1985;7(suppl 2): S5-S9.
9. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ (Clin Res Ed). 1986;293:1145-1151.
10. Perry HM Jr, Smith WM, McDonald RH, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke. 1989;20:4-13.
11. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
12. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
13. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
14. Gahlinger PM, Abramson JH, eds. CASECONT in Programs for Epidemiologic Analysis (PEPI), Version 2. Stone Mountain, Ga: USA Inc; 1995: 33-41.
15. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons; 1991.
16. Mehta CR, Patel N, Gray R. Computing an exact confidence interval for the common odds ratio in several 2 × 2 contingency tables. J Am Stat Assoc. 1985;80:969-973.
17. Ekbom T, Dahlof B, Hansson L, Lindholm LH, Schersten B, Wester PO. Antihypertensive efficacy and side effects of three β-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens. 1992;10:1525-1530.
18. Prichard BNC, Gillam PMS. Use of propranolol (Inderal) in treatment of hypertension. BMJ. 1964; 2:725-727.
19. Lever AF, Brennan PJ. MRC trial of treatment in elderly hypertensives. High Blood Press. 1992;1: 132-137.
20. Hoes AW, Grobbee DE, Lubsen J, Man in't Veld AJ, van der Does E, Hofman A. Diuretics, β-blockers. and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med. 1995;123:481-487.
21. Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am J Hypertens. 1995;8 (12 pt 1):1147-1153.
22. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension. 1994;23: 275-285.
23. The MRC working party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97-104.
24. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol. J Hypertens. 1985;3:379-392.
25. Wilhelmsen L, Berglund G, Elmfeldt D, et al. β-blockers versus diuretics in hypertensive men. J Hypertens. 1987;5:561-572.
26. Staessen J, Fagard R, Amery A. Primary Prevention With Metoprolol in Patients With Hypertension [letter]. JAMA. 1988;260:1713-1714.
27. Messerli FH, Sundgaard-Riise K, Ventura HO, Dunn FG, Glade LB, Frohlich ED. Essential hypertension in the elderly. Lancet. 1983;2:983-986.
28. Lund-Johansen P, Omvik P. Hemodynamic patterns of untreated hypertensive disease. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. Vol 1. 2nd ed. New York, NY: Raven Press Ltd; 1995:323-342.
29. Lund-Johansen P. Hemodynamic consequences of long-term β-blocker therapy. J Cardiovasc pharmacol. 1979;1:487-495.
30. Man in't Veld AJ, Van Den Meiracker AH, Schalekamp MA. Do β-blockers really increase peripheral vascular resistance? Am J Hypertens. 1988; 1:91-96.
31. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
32. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. JAMA. 1996;275:1507-1513.
33. Schulman SP, Weiss JL, Becker LC, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med. 1990; 322:1350-1356.
34. Neaton JD, Grim RH Jr, Prineas RJ, et al, for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270:713-724.
35. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation. 1997;95: 2007-2014.
36. Hollenberg NK, Epstein M, Basch RI, Merrill JP. "No man's land" of the renal vasculature. Am J Med. 1969;47:845-854.
37. London GM, Safar ME, Sassard JE, Levenson JA, Simon AC. Renal and systemic hemodynamics in sustained essential hypertension. Hypertension. 1984;6:743-754.
38. Schmieder RE, Schächinger H, Messerli FH. Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension. 1994;23:351-357.
39. de Leeuw PW, Gaillard CA, Birkenhäger WH. Renal hemodynamic patterns in essential hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology Diagnosis, and Management. Vol 2. 2nd ed. New York, NY: Raven Press Ltd; 1995:1857-1867.
40. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155: 1073-1080.
41. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129-138.
42. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med. 1984;310:356-360.
43. Bauer JH. Diabetic nephropathy: can it be prevented? South Med J. 1994;87:1043-1053.
44. Bauer JH, Brooks CS. The long-term effect of propranolol therapy on renal function. Am J Med. 1979;66:405-410.
45. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-504.
46. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83-91.
47. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor: comparison with effects of a β-blocker. Am J Hupertens. 1995;8:229-236.
48. Skarfors ET, Lithell HO, Selinus I, Åberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ. 1989;298:1147-1152.
49. Bengtsson C, Blohmé G, Lapidus L, Lissner L, Lundgren H. Diabetes incidence in users and nonusers of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12-year prospective population study of women in Gothenburg, Sweden. J Intern Med. 1992;231:583-588.
50. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol. BMJ. 1989;298:1152-1157.
51. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992;1:92-101.
52. Skarfors ET, Lithell HO, Selinus I, Åberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989;298:1147-1152.
53. Weidmann P, Ferrier C, Saxenhofer H, Uehlinger DE, Trost BN. Serum lipoproteins during treatment with antihypertensive drugs. Drugs. 1988;35(suppl 6):118-134.
54. Grimm RH Jr. Antihypertensive therapy: taking lipids into consideration. Am Heart J. 1991;122: 910-918.
55. Roberts WC. Recent studies on the effects of beta blockers on blood lipidlevels. Am Heart J. 1989; 117:709-714.
56. van Brummelen P, Buhler FR, Kiowski W, Amann FW. Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline. Clin Sci (Colch). 1981;60:571-577.
57. Kasiske RL, Ma JZ, Kalil RSN, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122:133-141.
58. Lakatta EG, Gerstenblith G, Angell CS, Shock NW, Weisfeldt ML. Diminished inotropic response of aged myocardium to catecholamines. Circ Res. 1975;36:262-269.
59. Guarnieri T, Filburn CR, Zitnik G, Roth GS, Lakatta EG. Contractile and biochemical correlates of β-adrenergic stimulation of the aged heart. Am J Physiol. 1980;239:H501-H508.
60. Feldman RD, Limbird LE, Nadeau J, Robertson D, Wood AJ. Alterations in leukocyte β-receptor affinity with aging. N Engl J Med. 1984;310: 815-819.
61. Stratton JR, Cerqueira MD, Schwartz RS, et al. Differences in cardiovascular responses to isoproterenol in relation to age and exercise training in healthy men. Circulation. 1992;86:504-512.
62. Vlachakis ND, Aledort L. Hypertension and propranolol therapy. Am J Cardiol. 1980;45:321-325.
63. Fleg JL, Schulman S, O'Connor F, et al. Effects of acute β-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. Circulation. 1994;90:2333-2341.